• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Ireland·Consumer Cyclical·GL9.IR
Share

Glanbia plc Stocks

€ 20.24Last Updated 23.10.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

€ 5.53B

€ 20.24
Key Takeaways

Risk factor

Low price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Decent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Latest news

20.06.2026 16:01

Small caps last week: Anthropic IPO beneficiaries, GLP-1 craze winners, biotech rally

17.06.2026 17:50

Protein-powder maker Glanbia seen as rare food-sector beneficiary of GLP-1 craze

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Operating globally as a prominent nutrition company, Glanbia plc specializes in the development and distribution of sports and lifestyle nutrition products. These offerings come in various forms, including powdered supplements, ready-to-eat bars, convenient snacking foods, and prepared beverages. The company reaches consumers through a wide array of distribution channels, encompassing specialty retailers, online platforms, fitness centers, and larger retail environments such as food, drug, mass-market, and club stores. Additionally, Glanbia is a key producer of cheese, a diverse range of dairy and non-dairy nutritional and functional ingredients, and vital vitamin and mineral premixes. Its operational scope extends beyond product manufacturing to include activities such as financing, research and development, property management, receivables handling, general business administration, property leasing, various business services, and weight management solutions. The company boasts a robust portfolio of renowned brands, including OPTIMUM NUTRITION, SlimFast, BSN, ISOPURE, NUTRAMINO, think!, Amazing Grass, and BODY&FIT. Glanbia plc was founded in 1964 and maintains its corporate headquarters in Kilkenny, Ireland.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA, r

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of GL9.IR is 24.0 and suggests 18.6% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

24.10.2026 16:01

Highlights in Small-Cap Stocks: The Merck Deal, the Success of a Hair Loss Pill, and Braze's "Wow Factor"

24.10.2026 13:01

AI investors are already on the brink, a “French kiss” for the euro, and hackers at the gates

24.10.2026 05:04

Hedge funds have ramped up their bets against the euro to a 2020 high

24.10.2026 04:46

France Avoided a Downgrade by Moody’s After a Week of Crisis

24.10.2026 04:37

A key Novartis drug failed to meet expectations. The stock price fell

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026